Key result
Increasing edoxaban use to 75% by 2030 in a European AF population is projected to reduce thromboembolism and death from 5.67 to 5.42 events per million patients per year.
Why the study?
Does increasing the use of edoxaban compared to warfarin reduce thromboembolism, death, and economic costs in a European AF population?
Does increasing the use of edoxaban compared to warfarin reduce thromboembolism, death, and economic costs in a European AF population?
Absolute Event Rate: 5.42% vs 5.67%
Modelling suggests that increasing the uptake of edoxaban over warfarin in European AF patients could substantially reduce the clinical and economic burden of stroke and thromboembolism through 2050.
No takes yet. Share an insight, caveat, or question.
Edoxaban may be cost-effective for AF stroke prevention in Europe; extends modeling but leaves open real-world validation.
Blann et al. (2016) studied Atrial fibrillation. Edoxaban vs. Warfarin was evaluated on Rate of thromboembolism and death. Increasing edoxaban use to 75% by 2030 in a European AF population is projected to reduce thromboembolism and death from 5.67 to 5.42 events per million patients per year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: